Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Angiotensin Receptor‐Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real‐World Data

Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Angiotensin Receptor‐Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real‐World Data

Background Contemporary use of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) and angiotensin receptor‐neprilysin inhibitors (ARNi) in patients with atrial fibrillation (AF) and heart failure (HF) has not been described. Methods and Results We analyzed the MarketScan databases for the period Jan...

Full description

Bibliographic Details
Main Authors: Alvaro Alonso, Alanna A. Morris, Ashley I. Naimi, Aniqa B. Alam, Linzi Li, Vinita Subramanya, Lin Yee Chen, Pamela L. Lutsey
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
angiotensin receptor‐neprilysin inhibitors
atrial fibrillation
heart failure
sodium‐glucose cotransporter‐2 inhibitors
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.123.032783

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.123.032783

Similar Items